Multiparametric prostate mr imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences : Are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy

Radiology

Volumn 268, Issue 2, 2013, Pages 440-450

  Donati, Olivio F ^a   Jung, Sung Il ^a,e   Vargas, Hebert Alberto ^a   Gultekin, David H ^b   Zheng, Junting ^c   Moskowitz, Chaya S ^c   Hricak, Hedvig ^a   Zelefsky, Michael J ^d   Akin, Oguz ^a  

^a Section of Radiology   (United States)

^b Medical Physics   (United States)

^c Biostatistics ^*  (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Konkuk University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; AREA UNDER THE CURVE; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DISEASE DURATION; DYNAMIC CONTRAST MATERIAL ENHANCED MAGNETIC RESONANCE IMAGING; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INFORMED CONSENT; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSERVER VARIATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; QUANTITATIVE ANALYSIS; RADIATION DOSE; RANK SUM TEST; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; T2 WEIGHTED MAGNETIC RESONANCE IMAGING; VOLUME TRANSFER CONSTANT;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOPSY; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84880681532     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13122149     Document Type: Article

References (37)

1. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8(6):475-487.
2. Caloglu M, Ciezki J. Prostate-specific antigen bounce after prostate brachytherapy: Review of a confusing phenomenon. Urology 2009;74(6):1183-1190.
3. Horwitz EM, Levy LB, Thames HD, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: A multiinstitutional pooled analysis. Cancer 2006;107(7):1496-1502.
4. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 2005;173(5):1456-1462.
5. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166(1):86-91; discussion 91-92.
6. Boukaram C, Hannoun-Levi JM. Management of prostate cancer recurrence after definitive radiation therapy. Cancer Treat Rev 2010;36(2):91-100.
7. Algaba F, Epstein JI, Aldape HC, et al. Assessment of prostate carcinoma in core needle biopsy: Definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996;78(2):376-381.
8. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17(3):292-306.
9. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: Multiparametric MR imaging for detection, localization, and staging. Radiology 2011;261(1):46-66.
10. Tamada T, Sone T, Jo Y, et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: The value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR Am J Roentgenol 2011;197(2):408-414.
11. Akin O, Gultekin DH, Vargas HA, et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the de tection of locally recurrent prostate cancer after radiation treatment: Preliminary results. Eur Radiol 2011;21(9):1970-1978.
12. Arumainayagam N, Kumaar S, Ahmed HU, et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int 2010;106(7):991-997.
13. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70(2):425-430.
14. Chan TW, Kressel HY. Prostate and seminal vesicles after irradiation: MR appearance. J Magn Reson Imaging 1991;1(5):503-511.
15. Fuchsjäger M, Akin O, Shukla-Dave A, Pucar D, Hricak H. The role of MRI and MRSI in diagnosis, treatment selection, and posttreatment follow-up for prostate cancer. Clin Adv Hematol Oncol 2009;7(3):193-202.
16. Sala E, Eberhardt SC, Akin O, et al. Endorectal MR imaging before salvage prostatectomy: Tumor localization and staging. Radiology 2006;238(1):176-183.
17. Akin O, Hricak H. Imaging of prostate cancer. Radiol Clin North Am 2007;45(1):207-222.
18. Pucar D, Shukla-Dave A, Hricak H, et al. Prostate cancer: Correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005;236(2):545-553.
19. Vargas HA, Wassberg C, Akin O, Hricak H. MR imaging of treated prostate cancer. Radiology 2012;262(1):26-42.
20. Barrett T, Gill AB, Kataoka MY, et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study. Magn Reson Med 2012;67(3):778-785.
21. Røe K, Kakar M, Seierstad T, Ree AH, Olsen DR. Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: A preclinical study. Radiat Oncol 2011;6:65.
22. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-974.
23. de Bazelaire CM, Duhamel GD, Rofsky NM, Alsop DC. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: Preliminary results. Radiology 2004;230(3):652-659.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988;44(3):837-845.
25. Obuchowski NA. Nonparametric analysis of clustered ROC curve data. Biometrics 1997;53(2):567-578.
26. Zhou XH, Obuchowski NA, McClish DK. Statistical methods in diagnostic medicine. 2nd ed. New York, NY: Wiley-Interscience, 2011.
27. Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas 1973;33(3):613-619.
28. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-174.
29. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-974.
30. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271(5):368-374.
31. Kobus T, Vos PC, Hambrock T, et al. Prostate cancer aggressiveness: In vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. Radiology 2012;265(2):457-467.
32. Oto A, Yang C, Kayhan A, et al. Diffusionweighted and dynamic contrast-enhanced MRI of prostate cancer: Correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 2011;197(6):1382-1390.
33. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011;258(2):488-495.
34. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: Tumor detection and assessment of aggressiveness. Radiology 2011;259(3):775-784.
35. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22(4):746-757.
36. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164(2):400-404.
37. Westphalen AC, Reed GD, Vinh PP, Sotto C, Vigneron DB, Kurhanewicz J. Multiparametric 3T endorectal MRI after external beam radiation therapy for prostate cancer. J Magn Reson Imaging 2012;36(2):430-437.